Pharmacological inhibition of CXCR2/ERK, the signaling pathway downstream of CXCL1 and CXCL2, could markedly decrease CSC activity and sensitize HCC cells to SOR. This evidence concerns the gene CXCR2 and hepatocellular carcinoma.